Shares in Pfizer and Moderna fell 3.9% and 7.4%, respectively, Friday after a report that the Trump administration plans to link the deaths of 25 children to COVID vaccines.Trump health officials plan to include the claim in a presentation next week to a panel of advisors to the CDC that is considering new COVID vaccine recommendations, which can impact access to the shots and whether they’re free, according to the Washington Post.Those deaths were seemingly gathered from information submitted to the govern ...

We do have a news alert today on COVID vaccines and for that we'll turn back to Angelica Peebles. Hi Angelica. Hey Carl.Well the Washington Post is reporting that Trump health officials plan to link coronavirus vaccines to the deaths of 25 children and that is that comes as next week this um the CDC advisers on vaccines will weigh how those co vaccines should be used going forward. This has obviously been a very contentious issue and the Washington Post is citing people familiar with this. We of course have ...

We do have a news alert today on COVID vaccines and for that we'll turn back to Angelica Peebles. Hi Angelica. Hey Carl.Well the Washington Post is reporting that Trump health officials plan to link coronavirus vaccines to the deaths of 25 children and that is that comes as next week this um the CDC advisers on vaccines will weigh how those co vaccines should be used going forward. This has obviously been a very contentious issue and the Washington Post is citing people familiar with this. We of course have ...

Robert F. Kennedy Jr. ., the dangerous crank in charge of our country's health, severely restricted who can get COVID vaccines last week.And then the very next day, the two largest pharmacy chains, CVS and Walgreens, clap down on access the vaccine in over a dozen states. Not surprising that is how it works. Now, a growing number of states are bucking RFK Jr.., going their own way to ensure their residents can access the vaccine if they so choose. In Colorado, Governor Jared Polus announced he quote will no ...

The last word with Lawrence O'Donnell starts right now. Hey, Lawrence. >> Hey, Jen.We have uh Abigail Spamberger joining us tonight, candidate for governor in Virginia, the most important election of the year, as you know. Of course, >> my home state. >> Yeah.And uh it's always it's um it's as if some uh political science class designed this that there's always the governor's election in Virginia the year after the presidential election because Virginia has that one term limit >> for the governor four years ...

President Trump is taking aim at pharmaceutical companies, demanding that they release data on their co vaccines. The president posted on Truth Social yesterday, questioning whether the shots actually saved millions of lives. In fact, he said the issue is ripping the CDC apart.>> Meanwhile, critics see this all as an effort by President Trump to appeal to his MAGA base. His top health official, Robert F. Kennedy Jr.., has been accused of rejecting the science behind those vaccines, fueling a culture of skep ...

Summary of Pfizer (PFE) FY Conference - June 09, 2025 Industry Overview - The pharmaceutical industry is currently facing significant uncertainty due to potential policy changes in drug pricing, particularly related to the Most Favored Nation (MFN) executive order and tariffs [5][4][6] - There is a notable anxiety among investors, reflected in depressed stock multiples across the sector [5] Key Points from the Conference Drug Pricing and Policy - The MFN executive order is a major concern, with potential outcomes ranging from no changes to significant price adjustments in the U.S. and internationally [8][9] - The U.S. government has historically not pressured European countries to raise drug prices, but the current administration is showing a willingness to address this issue [12][14] - The U.S. spends approximately 0.8% of GDP per capita on innovative medicines, compared to 0.4% in Germany and 0.5% in Italy and Spain, indicating a disparity in drug pricing [16] - Pfizer may reconsider its launch strategies in Europe if significant price disparities between the U.S. and Europe persist, potentially opting to remove products from reimbursement rather than withdrawing them entirely [17][18] Financial Performance and Guidance - Pfizer's financial outlook for 2025 is optimistic, with strong revenue and cost control measures in place, leading to expected margin expansion [31][32] - The company reported higher-than-expected revenues in Q1, but COVID-19 remains a wildcard, with potential revenue impacts depending on the pandemic's trajectory [33][34] Cost Management and Operational Efficiency - Pfizer plans to achieve $1.7 billion in operational expense reductions over the next two years, with $1.2 billion targeted for selling, general, and administrative expenses (SG&A) and $500 million for R&D [40][41] - The company is leveraging technology, automation, and simplification to enhance productivity without compromising top-line performance [41][42] Mergers and Acquisitions (M&A) - Pfizer's recent acquisition of a PD-1 VEGF bispecific asset from 3S Bio for an initial $1.2 billion, with potential total costs reaching $6 billion based on milestones, reflects a strategic focus on promising oncology assets [46][48] - The company is cautious about overpaying for assets, particularly in the context of pricing pressures and competition in the obesity and cardiometabolic sectors [56][59] Dividend and Capital Allocation - Pfizer is committed to maintaining and growing its dividend, viewing it as a high priority alongside deleveraging and strategic investments [60][61] - The company has the capacity for M&A within a $10 billion to $15 billion range, preferring smaller, strategic deals over larger acquisitions [59] Product Pipeline and Competitive Landscape - Pfizer is optimistic about its pipeline, particularly in obesity and multiple myeloma, with upcoming readouts expected to enhance commercial opportunities [63][65] - The company is confident in its competitive positioning against emerging therapies, particularly in the context of its established products and market presence [67][70] Additional Insights - The administration's focus on tariffs and manufacturing investments in the U.S. could impact Pfizer's future capital allocation decisions [26][28] - The company is actively working to ensure that any regulatory changes do not undermine the pharmaceutical industry's sustainability [24][30]